DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer

Clinical Epigenetics

Volumn 7, Issue 1, 2015, Pages

  Johnson, Kevin C ^a   Koestler, Devin C ^b   Fleischer, Thomas ^c,d   Chen, Panpan ^a   Jenson, Erik G ^a   Marotti, Jonathan D ^a   Onega, Tracy ^a,e   Kristensen, Vessela N ^c,d,f   Christensen, Brock C ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d UNIVERSITY OF OSLO   (Norway)

^e DARTMOUTH INSTITUTE FOR HEALTH POLICY AND CLINICAL PRACTICE   (United States)

^f AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Array; Breast; Cancer; DCIS; Methylation; TCGA

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EARLY CANCER; EPIGENETICS; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; GENE EXPRESSION REGULATION; GENOME ANALYSIS; HUMAN; HUMAN TISSUE; INTRADUCTAL CARCINOMA; MAMMOGRAPHY; MORPHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; TUMOR INVASION;

EID: 84938418481     PISSN: 18687075     EISSN: 18687083     Source Type: Journal    
DOI: 10.1186/s13148-015-0094-0     Document Type: Article

References (56)

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29. doi:10.3322/caac.21254.
2. Warren JL, Weaver DL, Bocklage T, Key CR, Platz CE, Cronin KA, et al. The frequency of ipsilateral second tumors after breast-conserving surgery for DCIS: a population based analysis. Cancer. 2005;104(9):1840–8. doi:10.1002/cncr.21406.
3. Hartmann LC, Sellers TA, Frost MH, Lingle WL, Degnim AC, Ghosh K, et al. Benign breast disease and the risk of breast cancer. N Engl J Med. 2005;353(3):229–37. doi:10.1056/NEJMoa044383.
4. Duggal S, Julian TB. A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ. J Natl Cancer Inst. 2013;105(10):681–3. doi:10.1093/jnci/djt098.
5. van Hoesel AQ, Sato Y, Elashoff DA, Turner RR, Giuliano AE, Shamonki JM, et al. Assessment of DNA methylation status in early stages of breast cancer development. Br J Cancer. 2013;108(10):2033–8. doi:10.1038/bjc.2013.136.
6. Group EBCC, Group ER, Bijker N, Meijnen P, Peterse JL, Bogaerts J, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Cancer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol Off J Am Soc Clini Oncol. 2006;24(21):3381–7. doi:10.1200/JCO.2006.06.1366.
7. Wickerham DL, Julian TB. Ductal carcinoma in situ: a rose by any other name. J Natl Cancer Inst. 2013;105(20):1521–2. doi:10.1093/jnci/djt268.
8. Marshall E. Breast cancer. Dare to do less Science. 2014;343(6178):1454–6. doi:10.1126/science.343.6178.1454.
9. Pace LE, Keating NL. A systematic assessment of benefits and risks to guide breast cancer screening decisions. JAMA. 2014;311(13):1327–35. doi:10.1001/jama.2014.1398.
10. Muggerud AA, Ronneberg JA, Warnberg F, Botling J, Busato F, Jovanovic J, et al. Frequent aberrant DNA methylation of ABCB1, FOXC1, PPP2R2B and PTEN in ductal carcinoma in situ and early invasive breast cancer. Breast cancer research: BCR. 2010;12(1):R3. doi:10.1186/bcr2466.
11. Stefansson OA, Esteller M. Epigenetic modifications in breast cancer and their role in personalized medicine. Am J Pathol. 2013;183(4):1052–63. doi:10.1016/j.ajpath.2013.04.033.
12. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia. 2010;15(1):5–17. doi:10.1007/s10911-010-9165-1.
13. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet. 2012;13(7):484–92. doi:10.1038/nrg3230.
14. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109(8):2802–7. doi:10.1073/pnas.1108781108.
15. Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. doi:10.1038/nature11412.
16. Fang F, Turcan S, Rimner A, Kaufman A, Giri D, Morris LG, et al. Breast cancer methylomes establish an epigenomic foundation for metastasis. Science translational medicine. 2011;3(75):75–25. doi:10.1126/scitranslmed.3001875.
17. Christensen BC, Kelsey KT, Zheng S, Houseman EA, Marsit CJ, Wrensch MR, et al. Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet. 2010;6(7), e1001043. doi:10.1371/journal.pgen.1001043.
18. Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002;21(35):5462–82. doi:10.1038/sj.onc.1205606.
19. Klajic J, Fleischer T, Dejeux E, Edvardsen H, Warnberg F, Bukholm I, et al. Quantitative DNA methylation analyses reveal stage dependent DNA methylation and association to clinico-pathological factors in breast tumors. BMC Cancer. 2013;13:456. doi:10.1186/1471-2407-13-456.
20. Moelans CB, Verschuur-Maes AH, van Diest PJ. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol. 2011;225(2):222–31. doi:10.1002/path.2930.
21. Tommasi S, Karm DL, Wu X, Yen Y, Pfeifer GP. Methylation of homeobox genes is a frequent and early epigenetic event in breast cancer. Breast cancer research: BCR. 2009;11(1):R14. doi:10.1186/bcr2233.
22. Pang JM, Dobrovic A, Fox SB. DNA methylation in ductal carcinoma in situ of the breast. Breast cancer research: BCR. 2013;15(3):206. doi:10.1186/bcr3420.
23. Monti S, Tamayo P, Mesirov J, Golub T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn. 2003;52(1–2):91–118. doi:10.1023/A:1023949509487.
24. Fleischer T, Frigessi A, Johnson KC, Edvardsen H, Touleimat N, Klajic J, et al. Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. Genome Biol. 2014;15(8):435. doi:10.1186/PREACCEPT-2333349012841587.
25. Polyak K. Molecular markers for the diagnosis and management of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 2010;2010(41):210–3. doi:10.1093/jncimonographs/lgq019.
26. Aran D, Sabato S, Hellman A. DNA methylation of distal regulatory sites characterizes dysregulation of cancer genes. Genome Biol. 2013;14(3):R21. doi:10.1186/gb-2013-14-3-r21.
27. Fackler MJ, Umbricht CB, Williams D, Argani P, Cruz LA, Merino VF, et al. Genome-wide methylation analysis identifies genes specific to breast cancer hormone receptor status and risk of recurrence. Cancer Res. 2011;71(19):6195–207. doi:10.1158/0008-5472.CAN-11-1630.
28. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer—a mechanism for early oncogenic pathway addiction? Nat Rev Cancer. 2006;6(2):107–16. doi:10.1038/nrc1799.
29. Beltran AS, Graves LM, Blancafort P. Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. Oncogene. 2013. doi:10.1038/onc.2013.422.
30. Shah N, Jin K, Cruz LA, Park S, Sadik H, Cho S, et al. HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERalpha and inducing IL-6 expression. Cancer Res. 2013;73(17):5449–58. doi:10.1158/0008-5472.CAN-13-1178.
31. Rodriguez BA, Cheng AS, Yan PS, Potter D, Agosto-Perez FJ, Shapiro CL, et al. Epigenetic repression of the estrogen-regulated Homeobox B13 gene in breast cancer. Carcinogenesis. 2008;29(7):1459–65. doi:10.1093/carcin/bgn115.
32. Tomida S, Yanagisawa K, Koshikawa K, Yatabe Y, Mitsudomi T, Osada H, et al. Identification of a metastasis signature and the DLX4 homeobox protein as a regulator of metastasis by combined transcriptome approach. Oncogene. 2007;26(31):4600–8. doi:10.1038/sj.onc.1210242.
33. Kron K, Liu L, Trudel D, Pethe V, Trachtenberg J, Fleshner N, et al. Correlation of ERG expression and DNA methylation biomarkers with adverse clinicopathologic features of prostate cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012;18(10):2896–904. doi:10.1158/1078-0432.CCR-11-2901.
34. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57. doi:10.1038/Nprot.2008.211.
35. Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 2012;21(3):569–76. doi:10.1093/hmg/ddr491.
36. Marsit CJ, Houseman EA, Christensen BC, Gagne L, Wrensch MR, Nelson HH, et al. Identification of methylated genes associated with aggressive bladder cancer. PLoS One. 2010;5(8), e12334. doi:10.1371/journal.pone.0012334.
37. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature. 2010;464(7291):1071–6. doi:10.1038/nature08975.
38. Shah N, Sukumar S. The Hox genes and their roles in oncogenesis. Nat Rev Cancer. 2010;10(5):361–71. doi:10.1038/nrc2826.
39. MacKenzie TA, Titus-Ernstoff L, Vacek PM, Geller B, Weiss JE, Goodrich ME, et al. Breast density in relation to risk of ductal carcinoma in situ of the breast in women undergoing screening mammography. Cancer causes & control: CCC. 2007;18(9):939–45. doi:10.1007/s10552-007-9035-3.
40. Dumenil TD, Wockner LF, Bettington M, McKeone DM, Klein K, Bowdler LM, et al. Genome-wide DNA methylation analysis of formalin-fixed paraffin embedded colorectal cancer tissue. Genes Chromosomes Cancer. 2014;53(7):537–48. doi:10.1002/gcc.22164.
41. Lechner M, Fenton T, West J, Wilson G, Feber A, Henderson S, et al. Identification and functional validation of HPV-mediated hypermethylation in head and neck squamous cell carcinoma. Genome med. 2013;5(2):15. doi:10.1186/gm419.
42. S Moran, M Vizoso, A Martinez-Cardus, A Gomez, X Matias-Guiu, SM Chiavenna et al. Validation of DNA methylation profiling in formalin-fixed paraffin-embedded samples using the Infinium HumanMethylation450 Microarray. Epigenetics: official journal of the DNA Methylation Society. 2014;9(6).
43. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium Methylation 450K technology. Epigenomics. 2011;3(6):771–84. doi:10.2217/epi.11.105.
44. Koestler DC, Li J, Baron JA, Tsongalis GJ, Butterly LF, Goodrich M, et al. Distinct patterns of DNA methylation in conventional adenomas involving the right and left colon. Modern pathology: an official journal of the United States and Canadian Academy of Pathology, Inc. 2014;27(1):145–55. doi:10.1038/modpathol.2013.104.
45. Roessler J, Ammerpohl O, Gutwein J, Hasemeier B, Anwar SL, Kreipe H, et al. Quantitative cross-validation and content analysis of the 450k DNA methylation array from Illumina. Inc BMC research notes. 2012;5:210. doi:10.1186/1756-0500-5-210.
46. Morris TJ, Butcher LM, Feber A, Teschendorff AE, Chakravarthy AR, Wojdacz TK, et al. ChAMP: 450k Chip Analysis Methylation Pipeline. Bioinformatics. 2014;30(3):428–30. doi:10.1093/bioinformatics/btt684.
47. Teschendorff AE, Marabita F, Lechner M, Bartlett T, Tegner J, Gomez-Cabrero D, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics. 2013;29(2):189–96. doi:10.1093/bioinformatics/bts680.
48. Johnson WE, Li C, Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics. 2007;8(1):118–27. doi:10.1093/biostatistics/kxj037.
49. Wilkerson MD, Hayes DN. ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking. Bioinformatics. 2010;26(12):1572–3. doi:10.1093/bioinformatics/btq170.
50. Jones JL. Overdiagnosis and overtreatment of breast cancer: progression of ductal carcinoma in situ: the pathological perspective. Breast cancer research: BCR. 2006;8(2):204. doi:10.1186/bcr1397.
51. Huang DW, Sherman BT, Lempicki RA. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucleic Acids Res. 2009;37(1):1–13. doi:10.1093/Nar/Gkn923.
52. Squazzo SL, O’Geen H, Komashko VM, Krig SR, Jin VX, Jang SW, et al. Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res. 2006;16(7):890–900. doi:10.1101/Gr.5306606.
53. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, et al. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet. 2007;39(2):232–6. doi:10.1038/Ng1950.
54. Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al. Control of developmental regulator’s by polycomb in human embryonic stem cells. Cell. 2006;125(2):301–13. doi:10.1016/J.Cell.2006.02.043.
55. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K. Genome-wide mapping of Polycomb target genes unravels their roles in cell fate transitions. Gene Dev. 2006;20(9):1123–36. doi:10.1101/Gad.381706.
56. Karolchik D, Hinrichs AS, Furey TS, Roskin KM, Sugnet CW, Haussler D, et al. The UCSC Table Browser data retrieval tool. Nucleic Acids Res. 2004;32:D493–6. doi:10.1093/Nar/Gkh103.